TY - JOUR
T1 - Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission
AU - Mischnik, Alexander
AU - Baumert, Philipp
AU - Hamprecht, Axel
AU - Rohde, Anna
AU - Peter, Silke
AU - Feihl, Susanne
AU - Knobloch, Johannes
AU - Gölz, Hanna
AU - Kola, Axel
AU - Obermann, Birgit
AU - Querbach, Christiane
AU - Willmann, Matthias
AU - Gebhardt, Friedemann
AU - Tacconelli, Evelina
AU - Gastmeier, Petra
AU - Seifert, Harald
AU - DZIF-ATHOS Study Group
AU - Kern, Winfried V.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - As part of the multicentre Antibiotic Therapy Optimisation Study (ATHOS), minimum inhibitory concentrations (MICs) were determined for cephalosporins alone and in combination with the β-lactamase inhibitors tazobactam, clavulanic acid and avibactam against third-generation cephalosporin-resistant Escherichia coli, Klebsiella spp. and Enterobacter spp. isolates collected in German hospitals. MIC50/90 values were 0.25–4 mg/L for cefepime/tazobactam, 0.25–2 mg/L for ceftazidime/avibactam, 0.125–0.5 mg/L for ceftaroline/avibactam, 0.5–4 mg/L for cefpodoxime/clavulanic acid and 0.25–1 mg/L for aztreonam/avibactam, depending on the underlying resistance mechanism and organism. Based on in vitro testing, β-lactam antibiotics play an important role in the treatment of infections due to β-lactamase-producing organisms.
AB - As part of the multicentre Antibiotic Therapy Optimisation Study (ATHOS), minimum inhibitory concentrations (MICs) were determined for cephalosporins alone and in combination with the β-lactamase inhibitors tazobactam, clavulanic acid and avibactam against third-generation cephalosporin-resistant Escherichia coli, Klebsiella spp. and Enterobacter spp. isolates collected in German hospitals. MIC50/90 values were 0.25–4 mg/L for cefepime/tazobactam, 0.25–2 mg/L for ceftazidime/avibactam, 0.125–0.5 mg/L for ceftaroline/avibactam, 0.5–4 mg/L for cefpodoxime/clavulanic acid and 0.25–1 mg/L for aztreonam/avibactam, depending on the underlying resistance mechanism and organism. Based on in vitro testing, β-lactam antibiotics play an important role in the treatment of infections due to β-lactamase-producing organisms.
UR - http://www.scopus.com/inward/record.url?scp=85008214271&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2016.10.013
DO - 10.1016/j.ijantimicag.2016.10.013
M3 - Journal articles
C2 - 27939093
AN - SCOPUS:85008214271
SN - 0924-8579
VL - 49
SP - 239
EP - 242
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 2
ER -
